Establishes a medical psilocybin advisory board to assess the use of psilocybin for therapeutic purposes.
New Hampshire HB1809 establishes a medical psilocybin advisory board to evaluate the clinical, quality, and public health aspects of using psilocybin for therapeutic purposes. The board will review medical evidence, identify clinical outcomes, and assess the efficacy of a therapeutic psilocybin program in New Hampshire. The board consists of experts from various fields, including medical psilocybin researchers, administrative representatives, and representatives from addiction services, palliative care, veterans' affairs, naturopathy, registered nursing, and mental health counseling.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.